398 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 12,752 published Tirzepatide COA source records from third-party laboratories, covering 1,778 publicly attributable vendor identities. Across 11,832 records with positive numeric purity, the arithmetic mean is 99.68%. 143 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 25 positive purity results are below 90%; 598 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.50 | $5.50–$7.50 | $1.30 | 2 sources · 2 offers |
| 10 mg | $8.88 | $8.00–$9.50 | $0.89 | 4 sources · 4 offers |
| 15 mg | $9.67 | $8.50–$10.50 | $0.64 | 3 sources · 3 offers |
| 20 mg | $11.33 | $10.50–$12.00 | $0.57 | 3 sources · 3 offers |
| 30 mg | $15.00 | $12.50–$17.00 | $0.50 | 4 sources · 4 offers |
| 40 mg | $19.88 | $18.00–$23.00 | $0.50 | 4 sources · 4 offers |
| 50 mg | $22.25 | $22.00–$22.50 | $0.45 | 2 sources · 2 offers |
| 60 mg | $26.12 | $25.00–$27.50 | $0.44 | 4 sources · 4 offers |
| 100 mg | $35.00 | $35.00–$35.00 | $0.35 | 1 source · 1 offer |
| 120 mg | $37.00 | $37.00–$37.00 | $0.31 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T05:08:44.388787+00:00. Calculation time is not a laboratory observation date.
Within that total, 3066 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 241 | 99.6% | 0 of 229 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 195 | 99.53% | 0 of 183 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #3 | 136 | 99.78% | 0 of 96 (0.0%) 0 0% / not detected · 0 wrong compound · 40 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120707 (99.88%) · #120652 (99.93%) · #120647 (99.96%) · #120646 (99.94%) · #120632 (99.9%) · #120622 (99.91%)
Understanding the rewired `IL-10` signaling and transcriptomic landscape in **MASLD-associated HCC** offers crucial insights for future therapeutic strategies. **Identifying these specific molecular shifts could lead …
**Tirzepatide**'s potential to modify **obstructive sleep apnea (OSA)** beyond weight loss could revolutionize treatment paradigms. For individuals with **obesity-related OSA**, this suggests a future where pharmacolo…
Obesity significantly promotes cancer development by inducing chronic metaflammation, metabolic reprogramming, and immune evasion, impacting several cancer hallmarks.
**Tirzepatide** is being evaluated in a 72-week randomized, placebo-controlled trial for body weight reduction in participants with obesity or overweight.
**Combining bremelanotide with tirzepatide could offer a more potent and comprehensive strategy for obesity management**, potentially overcoming limitations of current monotherapies. For individuals struggling to achi…
This trial represents a significant step towards a novel, non-surgical treatment for **endometrial cancer** in overweight women. If successful, **Tirzepatide** could offer a critical option for **fertility preservatio…
**Preserving lean muscle mass during significant weight loss with GLP-1/GIP agonists is a critical health goal.** This trial aims to provide evidence on whether adding structured exercise to **semaglutide** or **tirze…
This preclinical study offers compelling evidence that **tirzepatide** could serve as a promising adjunctive therapy to enhance the cardiac safety profile of `DOX` chemotherapy. For clinicians, this opens a new avenue…
**Clinicians gain an updated, comprehensive perspective on the latest therapeutic options for Heart Failure**, integrating new pharmacotherapies, device strategies, and emerging biological approaches. This review help…
**Integrating tailored lifestyle interventions with OMMs is crucial for optimizing long-term patient outcomes and shifting obesity care towards a health-centered model.** For clinicians and patients, this means moving…
**Early intervention with tirzepatide offers significantly better and more durable glycemic control, weight loss, and waist circumference reduction than current standard-of-care intensification strategies in early T2D…
This network meta-analysis provides crucial, dosage-specific evidence for treating **MASLD** patients with F1-F3 fibrosis, a population with high unmet medical need. **Clinicians and biohackers can now consider specif…
This review underscores that **GLP-1-based therapies represent a promising, phenotypically targeted approach for managing obesity-associated HFpEF**, offering significant improvements in patient-centric outcomes like …
This review underscores a critical shift towards an **integrated, phenotype-driven approach** for managing cardiac arrhythmias in patients with obesity and OSA. For peptide users and clinicians, it highlights **tirzep…
This comprehensive review highlights a significant potential paradigm shift in the management of **obesity-related obstructive sleep apnea (OSA)**, suggesting that **tirzepatide** could offer true disease modification…
This review significantly strengthens the case for **GLP-1RAs** as a viable pharmacological strategy for **AUD**, offering a much-needed alternative to current limited treatments. For peptide users and clinicians, thi…
This review provides a critical roadmap for advancing **precision medicine** in **Tirzepatide** therapy. **Identifying these predictors could enable clinicians to personalize treatment strategies, optimize dosing, and…
This report provides crucial guidance for clinicians, particularly nurse practitioners, on navigating the complex landscape of `GLP-1` use. **Providers must proactively educate patients on the dangers of unregulated c…
**Clinicians and individuals using tirzepatide must prioritize individualized risk-benefit assessment**, especially given the noted high risk of severe gastrointestinal events and potential impact on skeletal muscle m…
This perspective fundamentally shifts how clinicians and individuals should approach **GLP-1 RA** therapy for **obesity** and **type 2 diabetes**. **It underscores that these powerful medications are most effective wh…
Addressing the clinical support gap in telehealth **GLP-1** management is crucial for realizing the full potential of these transformative medications. For peptide users and clinicians, this means that simply prescrib…
This analysis highlights that not all `GLP-1RAs` carry the same risk profile for specific biliary adverse events, challenging the notion of class homogeneity. **Clinicians and individuals using GLP-1RAs should conside…
This meta-analysis provides robust evidence supporting **semaglutide as a promising adjunctive metabolic intervention for people with schizophrenia spectrum disorders**. Given the high burden of obesity and metabolic …
This model provides crucial insights for clinicians counseling patients with **advanced CKD** and **morbid obesity**, emphasizing that the degree of weight loss is paramount for long-term survival. **Individualized, w…
**Tirzepatide shows promise as a novel strategy to prevent doxorubicin-induced cardiotoxicity**, offering a potential adjunctive therapy for cancer patients undergoing anthracycline chemotherapy. This finding could si…
**GLP-1 RA use before spine surgery could significantly improve patient recovery and quality of life**, extending benefits beyond just reducing complications. This suggests clinicians might consider GLP-1 RAs as part …
This initial Phase 1/2 study of SRSD384 is crucial for understanding its foundational human profile. If successful, it could pave the way for a novel therapeutic agent for obesity and T2DM, potentially offering a new …
This review significantly expands the understanding of GLP-1 RAs beyond diabetes and obesity, establishing their utility in heart failure management, particularly for HFpEF/HFmrEF. For clinicians and biohackers, this …
Understanding the profound cardiometabolic consequences of discontinuing GLP-1RAs and tirzepatide is critical for clinicians and patients. Long-term adherence to these medications is paramount to sustain their benefit…
Data-mining analysis confirms GLP-1 receptor agonists, including semaglutide and tirzepatide, are associated with dose-dependent dysesthesia and burning skin sensations.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
GLP-1 analogues could represent a novel, dual-benefit therapeutic option for patients with psoriasis who also contend with obesity or metabolic syndrome. This research suggests a new avenue for treatment, moving beyon…
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
A completed Phase 1 study characterized tirzepatide pharmacokinetics in 32 participants with normal to severe hepatic impairment after a single 5 mg SC dose.
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
The findings from this cost-effectiveness analysis could profoundly impact treatment paradigms for HFpEF patients with obesity in Germany. If tirzepatide demonstrates superior cost-effectiveness, it could become a cor…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
The completion of this Phase 2 trial for tirzepatide in NASH is a significant step, as it could potentially introduce a much-needed therapeutic option for a disease with no approved pharmacological treatments. If posi…
This head-to-head Phase 3 trial is crucial for understanding the comparative efficacy and safety of Tirzepatide versus Semaglutide in Type 2 Diabetes patients already on metformin. The results will directly inform cli…
Understanding how tirzepatide impacts adipose tissue inflammation and fibrosis, even after metabolic improvements, is crucial for refining obesity treatment strategies. If adipose inflammation persists despite weight …
While specific results are not yet available, this study's design highlights the ongoing effort to precisely understand tirzepatide's mechanisms beyond just weight loss. Understanding if tirzepatide impacts energy exp…
This methodological study is crucial for advancing the confidence and utility of real-world data in clinical research. Understanding the reliability of claims data emulation for cardiovascular outcomes could significa…
This review underscores tirzepatide's potential to redefine the pharmacologic management of obesity-related OSAS, offering a systemic approach beyond traditional mechanical or surgical interventions. For peptide users…
This registry holds significant implications for understanding the pleiotropic effects of tirzepatide beyond its established metabolic benefits. For peptide users and clinicians, the data could illuminate whether tirz…
This Phase 1 study is a crucial step in the development of LY3841136 as a potential new therapy for obesity and overweight, especially given its investigation in combination with tirzepatide, a highly effective dual G…
If positive, this trial could represent a significant advancement in the treatment of obstructive sleep apnea, particularly for individuals with co-morbid obesity. Tirzepatide could offer a pharmacological alternative…
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
Tirzepatide's SURMOUNT-MAINTAIN trial investigates the efficacy and safety of continued or reduced dosing for long-term weight maintenance in adults with obesity.
Free, no account — handy when you're working with Tirzepatide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account